Patiromer Sorbitex Calcium

帕替罗姆

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NamePatiromer Sorbitex Calcium
Drug Alias Name帕替罗默Patiromer calcium帕替柔莫Patiromer acetatePatiromer sorbitex calcium +[12
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium binders
TargetsPotassium
Therapy Area/IndicationsHyperkalemiaHypertensionHeart Failure +[5
Global Approved IndicationsHyperkalemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/10/21
Country/TerritoryCzechiaBelgiumBulgaria +[36
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesViforRelypsa Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesRelypsa Inc
Active IndicationsHyperkalemiaKidney Failure, ChronicRenal Insufficiency, Chronic
Inactive IndicationsHypertensionHeart Failure

Other Information

ATC CodeV03AE09
Related LinksWikipediaDrugBank